| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PPAPDC3 |
| Uniprot No | Q8NBV4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-271 aa |
| 活性数据 | MPASQSRARARDRNNVLNRAEFLSLNQPPKGGPEPRSSGRKASGPSAQPPPAGDGARERRQSQQLPEEDCMQLNPSFKGIAFNSLLAIDICMSKRLGVCAGRAASWASARSMVKLIGITGHGIPWIGGTILCLVKSSTLAGQEVLMNLLLALLLDIMTVAGVQKLIKRRGPYEMSPSLLDYLTMDIYAFPAGHASRAAMVSKFFLSHLVLAVPLRVLLVLWALCVGLSRVMIGRHHVTDVLSGFVIGYLQFRLVELVWMPSSTCQMLISAW |
| 分子量 | 55.9 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与重组人PPAPDC3蛋白相关的参考文献摘要(部分为示例性整理，实际文献可能有限)：
1. **文献名称**: "Characterization of PPAPDC3 as a novel mitochondrial phosphatase involved in lipid metabolism"
**作者**: Smith A, et al.
**摘要**: 本研究首次成功在大肠杆菌中重组表达了人源PPAPDC3蛋白，并证实其具有磷酸酶活性，可水解特定磷脂酸。实验显示该蛋白定位于线粒体，可能参与调节细胞脂质稳态。
2. **文献名称**: "PPAPDC3 promotes tumor progression via MAPK signaling in colorectal cancer"
**作者**: Zhang L, et al.
**摘要**: 利用重组PPAPDC3蛋白进行功能研究发现，该蛋白通过激活MAPK通路增强结直肠癌细胞增殖和迁移，提示其可能作为癌症治疗的潜在靶点。
3. **文献名称**: "Structural insights into the catalytic mechanism of human PPAPDC3"
**作者**: Tanaka K, et al.
**摘要**: 通过X射线晶体学解析了重组PPAPDC3的三维结构，揭示了其催化活性位点及底物结合模式，为开发针对该蛋白的小分子抑制剂提供结构基础。
4. **文献名称**: "PPAPDC3 deficiency alters hepatic lipid metabolism in mice"
**作者**: Wang Y, et al.
**摘要**: 利用重组PPAPDC3蛋白补充实验，证明该蛋白缺失会导致小鼠肝脏甘油三酯积累异常，进一步验证其在脂代谢中的关键作用。
**注意**：以上文献信息为模拟示例，实际研究中针对PPAPDC3的专门文献较少，建议通过PubMed或Google Scholar以关键词“PPAPDC3”或“recombinant human PPAPDC3”检索最新成果。
**Background of Recombinant Human PPAPDC3 Protein**
PPAPDC3 (Phosphatidic Acid Phosphatase Type 2 Domain-Containing Protein 3) is a member of the phosphatidic acid phosphatase (PAP) family, which plays a role in lipid metabolism and signaling. This enzyme catalyzes the conversion of phosphatidic acid (PA) to diacylglycerol (DAG), a critical step in lipid biosynthesis and cellular signaling pathways. PPAPDC3 is characterized by a conserved phosphatase domain, though its substrate specificity and regulatory mechanisms remain less understood compared to other PAP family members.
The gene encoding PPAPDC3 is located on chromosome 19 in humans and is expressed in various tissues, with higher levels observed in the liver, brain, and reproductive organs. Studies suggest its involvement in diverse physiological processes, including cell proliferation, apoptosis, and membrane dynamics. Dysregulation of PPAPDC3 has been implicated in pathological conditions such as cancer, metabolic disorders, and neurodevelopmental abnormalities. For example, altered PPAPDC3 expression correlates with tumor progression and chemoresistance in certain cancers, potentially linked to its role in lipid-mediated signaling.
Recombinant PPAPDC3 protein is typically produced using eukaryotic expression systems (e.g., HEK293 or insect cells) to ensure proper post-translational modifications. It serves as a vital tool for *in vitro* studies to elucidate enzymatic activity, interactome analysis, and therapeutic targeting. Ongoing research aims to clarify its bifunctional roles in lipid homeostasis and disease pathogenesis, positioning PPAPDC3 as a potential biomarker or therapeutic target in metabolic and oncological contexts.
×
